Anti-PD-1 (Spartalizumab), Humanized Antibody

Anti-PD-1 (Spartalizumab), Humanized Antibodyis available at Gentaur for Next week Delivery.

Description: Spartalizumab is a humanized IgG4 monoclonal antibody developed by Novartis for the treatment of solid tumors as well as lymphomas. They act as negative immune regulators of programmed death-1 (PD-1), a transmembrane protein belonging to the immunoglobulin (Ig) superfamily. When administered, Spartalizumab binds to T-cells expressing PD-1 and thereby blocks the interaction between PD-1 and its ligands, programmed cell death 1 ligand 1 (PD-L1) and ligand 2 (PD-L2). Blocking the interaction disrupts PD-1 mediated signaling and results in activation of cytotoxic T lymphocytes and T cell mediated immune responses and thus inhibits the growth and size of the tumors. Ongoing clinical trials are evaluating the efficacy of this antibody for the treatment of metastatic pancreatic cancer and melanoma.

Immunogen Sequence:Spartalizumab

Target Alternative Name:PDCD1, PD1, CD279, SLEB2, hPD-1, hPD-l, PDR 001, PDR001

Species Reactivities:/

Tag Line:Spartalizumab (anti-PD-1) is a humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1. It binds to PD-1 with high affinity and inhibits the biological activity of PD-1

Formulation:In PBS buffer, pH 7.2

Purification: /

Application:In vivo studies

Positive Control:/

Application And Usages:In vivo studies

Handling:The antibody solution should be gently mixed before use.